Dr. Linda Kathleen Katz, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 100 John Sutherland Dr, Ste 3, Nicholasville, KY 40356 Phone: 859-881-1400 Fax: 859-881-3489 |
Dr. Micheal Bryan Minix Sr., MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 2 Olde Village Ct, Nicholasville, KY 40356 Phone: 859-219-1256 |
James H Patterson Jr., M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 104 Fairfield Dr, Nicholasville, KY 40356 Phone: 859-887-2441 Fax: 859-885-3323 |
News Archive
People who are exposed to paint, glue or degreaser fumes at work may experience memory and thinking problems in retirement, decades after their exposure, according to a study published in the May 13, 2014, print issue of Neurology®, the medical journal of the American Academy of Neurology.
Endocyte, Inc., a cancer drug discovery and development company, today announced it has received a milestone payment from Bristol-Myers Squibb Company (NYSE: BMY). This payment was triggered by the commencement of a Phase II clinical trial for an epothilone-folate anti-cancer agent identified through the collaboration between Endocyte and Bristol-Myers Squibb scientists.
Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
During its first week, California's insurance exchange received nearly 60,000 calls from consumers and about 1 million Web visitors. Despite numerous technical glitches, federal officials say 8 million people logged on last week to their online exchange for 36 states not running their own marketplace. This rollout has prompted many questions from people about what President Obama's Affordable Care Act will mean for them.
BD (Becton, Dickinson and Company)announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.
› Verified 2 days ago